Durvalumab

December 8, 2024

New Hope for Patients with Limited-Stage Small Cell Lung Cancer: FDA Approves IMFINZI

The FDA approval of IMFINZI for limited-stage small cell lung cancer is a momentous step forward, offering a much-needed new treatment option for patients facing this aggressive disease. As the first immunotherapy regimen approved in this setting, IMFINZI has the potential to redefine care and significantly improve outcomes. This milestone underscores the importance of continued research and innovation in the fight against lung cancer.
Easy Durvalumab Dosing – 2 MCQs
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more